Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
- Chief executive
- Dr. Thomas Schinecker
- Employees
- 103,249
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- CH
Profile observed 2026-08-13 03:08:33.780820+00 via eodhd.
Forecasts are available for Roche Holding AG's listed securities
A corporation provides context; forecasts attach to the exact market security and forecast target. Choose a related security below.
Identifiers & semantic identity
External identifiers, stable Library identity, and semantic-web assertions describe the same governed entity.
- Wikidata ID
- Q25463170
- Google Knowledge Graph MID
- /g/11bwdvn8sz
- Official website
- https://www.roche.com/
- iPulse entity ID
- fundsubj_9a37e9aa-b835-5b05-8d95-432488e35bd8
- Official Website Url
- https://www.roche.com/
- Wikipedia Url
- https://en.wikipedia.org/wiki/Roche_Holding
Relationship graph
2D · draggableThe blue forecastable node can receive forecast targets. Green context nodes explain who issues, owns, or hosts it.